Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Summary: Over the past 30 years, there has been a dramatic rise in global obesity prevalence, resulting in significant economic and social consequences. Attempts to develop pharmacological agents to treat obesity have met with many obstacles including the lack of long‐term effectiveness and the potential for adverse effects. Historically, there have been limited treatment options for overweight and obesity; however, since 2012, a number of new drugs have become available. A number of peptides produced in the gut act as key mediators of the gut–brain axis, which is involved in appetite regulation. This review discusses the role of the gut–brain axis in appetite regulation with special focus on glucagon‐like peptide‐1. Liraglutide 3.0 mg, a glucagon‐like peptide‐1 receptor agonist that targets this pathway, is now approved for the treatment of obesity and overweight (body mass index ≥27 kg/m 2) with comorbidities such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. In addition, other glucagon‐like peptide‐1 receptor agonists offer promise for obesity management in the future. This review examines how glucagon‐like peptide‐1 receptor agonists promote weight loss and summarizes the clinical data on weight loss with glucagon‐like peptide‐1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8mg in participants with T2D with positive results (73).”
BackgroundGuh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight
Kalra, S. P. (1999) · Endocrine Reviews · doi:10.1210/er.20.1.68 · Cited by 1,554
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“Infusions of native GLP-1 have been shown to reduce appetite in humans (27), and the once-daily GLP-1RA liraglutide 3.”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 2×
“0mg in SCALE Diabetes in participants with diabetes and obesity or overweight with comorbidities who were either drugnaïve or were receiving between one and three oral antidiabetic drugs (metformin, thiazolidinediones [TZD] and/or sulphonylurea [SU]) (51).”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“Consistent with reports from its use in treatment of T2D, trial data in participants with overweight and obesity showed liraglutide to have a good safety profile and be well tolerated, with no new safety concerns (49,52).”
ResultLarsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 2×
“0mg report nausea (43,52,70), which is a similar level as that reported in participants with T2D taking liraglutide 1.”
BackgroundResultThe gut and energy balance: visceral allies in the obesity wars
Badman, M. K., & Flier, J. S. (2005) · Science · doi:10.1126/science.1109951 · Cited by 532
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · cited 1×
“8mg treatment was associated with significantly more weight loss than albiglutide (61) and dulaglutide (64) and with more or similar weight loss compared with exenatide (57,65) (Table 3).”
ResultEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 1×
“Some publications have linked GLP-1 to mesolimbic brain areas, which are involved in the behavioural and motivational aspects of food reward (45), but these findings are disputed (46).”
BackgroundWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · cited 1×
“8mg treatment was associated with significantly more weight loss than albiglutide (61) and dulaglutide (64) and with more or similar weight loss compared with exenatide (57,65) (Table 3).”
ResultEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · cited 1×
“GLP-1RAs slow the rate of gastric emptying, thereby increasing feelings of fullness, which is suggested to be one mechanism by which GLP-1 regulates appetite (11).”
BackgroundRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · cited 1×
“A meta-analysis of the effects of GLP-1RAs on body weight in patients with T2D consistently shows a mean reduction in body weight of approximately 3 kg compared with other active diabetes treatments (including oral antidiabetic drugs and insulins) (25).”
ResultAhrén, B., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1030 · Cited by 292
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · cited 2×
“Exenatide treatment with and without metformin (MET) has been examined in a 24-week trial in overweight women (BMI >27kg/m(2)) with polycystic ovary syndrome (PCOS) (59).”
BackgroundRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Lifetime health and economic benefits of weight loss among obese persons.
Oster, G., Thompson, D., Edelsberg, J., Bird, A. P., & Colditz, G. A. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.10.1536 · Cited by 193
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · cited 1×
“Amylin is too unstable to be used clinically; however, a synthetic version (pramlintide) is already approved for use in diabetes and is being examined in clinical trials for use as an anti-obesity therapy in individuals without diabetes (20).”
BackgroundBolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Self-citationSloth, B., Davidsen, L., Holst, J. J., Flint, A., & Astrup, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2007 · Cited by 104 · cited 2×
“However, the therapeutic window for PYY3–36 is narrow, in terms of achieving reduced energy intake without the adverse side effects of nausea and vomiting (17,18).”
BackgroundGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26 · cited 2×
“In contrast, GLP-1RAs achieve twofold to 10-fold higher circulating concentration of GLP-1RA compared with endogenous GLP-1, so a direct action on the brain may be more likely (41,42).”
BackgroundSelf-citation
Research works printed but not linked: 36
- 10.1016/S0140-6736(14)60460-8 · DOI · Paper page
- Keum N, 2015, Adult weight gain and adiposity‐related cancers: a dose–response meta‐analysis of prospective observational studies, J Natl Cancer Inst, 107, 10.1093/jnci/djv088 · DOI · Paper page
- Apovian CM, 2013, The clinical and economic consequences of obesity, Am J Manag Care, 19, s219
- 10.2165/00019053-199400051-00007 · DOI · Paper page
- 10.1016/j.jacc.2013.11.004 · DOI · Paper page
- 10.1038/clpt.2013.204 · DOI · Paper page
- 10.1074/jbc.O114.556068 · DOI · Paper page
- 10.1155/2012/824305 · DOI · Paper page
- 10.1586/17446651.3.5.577 · DOI
- 10.1016/j.coph.2007.09.011 · DOI
- 10.1177/2040622313506730 · DOI · Paper page
- 10.1152/ajpendo.00450.2006 · DOI · Paper page
- 10.1900/RDS.2011.8.355 · DOI · Paper page
- 10.1152/physrev.00034.2006 · DOI · Paper page
- 10.1530/EJE-13-0264 · DOI · Paper page
- 10.1017/S0007114513002286 · DOI
- 10.2337/diabetes.50.3.609 · DOI · Paper page
- 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
- 10.1152/ajpregu.1999.276.5.R1541 · DOI · Paper page
- 10.3945/ajcn.112.047563 · DOI · Paper page
- 10.1111/j.1365-2036.2011.04609.x · DOI · Paper page
- 10.2337/db14-1514 · DOI · Paper page
- Lean M, 2015, The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise program, Endocr Pract, 21, 118, 10.1016/S1530-891X(20)42675-8 · DOI
- 10.1016/j.neuroimage.2006.12.035 · DOI
- 10.1172/JCI72434 · DOI · Paper page
- 10.2337/dc11-0931 · DOI · Paper page
- 10.1038/oby.2011.337 · DOI · Paper page
- 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- 10.2337/dc09-1203 · DOI · Paper page
- 10.2337/dc09-0366 · DOI · Paper page
- 10.1111/dom.12305 · DOI · Paper page
- 10.1002/oby.20042 · DOI · Paper page
- 10.2337/dc08-1961 · DOI · Paper page
- Blackman A, 2014, Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea trial, Diabetologia, 57, S85
- Saxenda® (Liraglutide 6 mg/ml), 2015, Summary of Product Characteristics
- 10.1177/0091270010367653 · DOI
Cited by
Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity
Timper, K., & Brüning, J. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026609 · Cited by 802
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Metadata
- Authors
- Burcelin, R., & Gourdy, P.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2016-09-16
- Volume
- 18
- Issue
- 1
- Pages
- 86-98
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2521423720
- Cited by
- 94
- References
- 37
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.